Paul Feuerstadt, MD, FACG, AGAF

Experts share advice for physicians taking care of patients with C. difficile infection (CDI).

Bincy Abraham, MD, MS; Thomas Lodise, PharmD, PhD; Teena Chopra, MD, MPH; and Paul Feuerstadt, MD, share unmet needs, including access to therapies, in treatment of C. difficile infection (CDI).

Experts discuss differences in designs of clinical trials of 4 emerging microbiota-based live biotherapeutics - RBX2660, SER-109, CP101, VE303, for treatment of rCDI.

Drs Abraham and Feuerstadt share recent data with emerging live biotherapeutic products, SER-109, CP101, and VE303, for treatment of recurrent C difficile infection (rCDI).

Drs Feuerstadt, Abraham, and Chopra discuss clinical trial data for RBX2660, a live biotherapeutic product, in treatment of recurrent C difficile infection (rCDI), as well as data with RBX2660 that were presented at DDW 2022.

Drs Chopra and Feuerstadt summarize challenges with current treatments and discuss live biotherapeutic products that are being studied for recurrent C difficile infection (rCDI).

Dr Lodise summarizes foundational trials that led to the use of fecal microbiota transplant for the treatment of rCDI.

Dr Teena Chopra shares her approach to monitoring patients with C difficile infection (CDI).

Drs Tom Lodise and Bincy Abraham provide an overview of fecal microbiota transplantation and long-term safety of FMT use.

Experts review treatment options for first, second and recurring episodes of Clostridioides difficile infection.

A gastroenterologist reviews the long-term impact of dysbiosis and Clostridioides difficile infection.

Dr. Tom Lodise provides an overview of gut microbiota and the consequences of dysbiosis.

Dr. Abraham discusses importance of differential diagnosis of C. difficile infection (CDI) in patients with IBD and how both IBD and CDI should be managed.

A gastroenterologist, Dr. Bincy Abraham, provides an overview of C. difficile infection (CDI) in patients with inflammatory bowel disease (IBD).

Drs. Lodise and Feuerstadt discuss educational opportunities to combat and reduce C. difficile infection (CDI).

Dr. Chopra shares multipronged approach to reducing C. difficile infection (CDI) and the role of antimicrobial stewardship.

Drs. Abraham, Chopra and Feuerstadt discuss importance of timely referral and diagnostic methods to discern C. difficile infection (CDI).

Drs Lodise and Feuerstadt discuss risk factors for C. difficile infection (CDI).

A gastroenterologist, Dr. Paul Feuerstadt, provides an overview of C. difficile infection (CDI) and vegetative and spore phases of CDI.

Fecal microbiota transplantation is proving to be an effective treatment for many patients with specific disorders associated with dysbiosis.